Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 58Breast Neoplasms 14Polycystic Ovary Syndrome 9Infertility 7Ovarian Hyperstimulation Syndrome 3Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Sarcoma, Ewing 2Sarcoma 2Prostate Adenocarcinoma 2Osteosarcoma 2Uterine Anomalies 1The Neoadjuvant Therapy 1Sleep Wake Disorders 1Salpingitis 1Salivary Gland Neoplasms 1Primary Ovarian Insufficiency 1Pregnancy, Ectopic 1Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Myofibroma 1Metabolic Syndrome 1Leiomyoma 1Infertility, Female 1Hypogonadism 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Helping Behavior 1Fatty Liver 1Fatigue 1

Interventions

Triptorelin Pamoate 1Paclitaxel 1Fulvestrant 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
The Neoadjuvant Therapy × Triptorelin Pamoate × Clear all
NCT04753177 2021-02-15

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary

Phase 2/3 Unknown
120 enrolled

The Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡